Memantina Gp

Memantine Hydrochloride, the active ingredient in Memantina Gp, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat Alzheimer’s disease in adult patients. GNH USA supplies Memantina Gp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is indicated for disorders of the central nervous system that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease. - Alzheimer’s disease (mild to moderate): helps maintain cognitive function and daily living activities. - Alzheimer’s disease (moderate to severe): may slow functional decline and improve global clinical status. - Alzheimer’s disease with behavioral disturbances: can reduce agitation and improve overall patient behavior.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel motility. - Confusion: occasional disorientation. - Fatigue: general tiredness. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Cardiac arrhythmia: irregular heart rhythm. - Severe hepatic injury: signs of liver dysfunction. - Stevens‑Johnson syndrome: serious skin reaction. - Suicidal ideation: thoughts of self‑harm. - Severe rash or hypersensitivity: extensive skin eruption.

Memantine Hydrochloride should be used with caution in specific clinical situations. - Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: consider dose reduction. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rhythm. - Concomitant NMDA agonists: avoid combined use due to antagonistic effects. - Store below 25°C: keep in the original pack, protect from moisture.

Memantine Hydrochloride can interact with several medication classes. Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuropsychiatric effects. - Other NMDA antagonists (e.g., ketamine): additive central nervous system depression. Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): may alter efficacy of each agent. - Antihypertensive drugs: potential additive blood pressure lowering. - Diuretics: monitor electrolyte balance. - SSRIs or SNRIs: watch for increased risk of confusion or dizziness.